JP2017518748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518748A5 JP2017518748A5 JP2016568907A JP2016568907A JP2017518748A5 JP 2017518748 A5 JP2017518748 A5 JP 2017518748A5 JP 2016568907 A JP2016568907 A JP 2016568907A JP 2016568907 A JP2016568907 A JP 2016568907A JP 2017518748 A5 JP2017518748 A5 JP 2017518748A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- glu
- gly
- arg
- lipocalin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 162
- 229920001184 polypeptide Polymers 0.000 claims description 153
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 153
- 102000013691 Interleukin-17 Human genes 0.000 claims description 55
- 108050003558 Interleukin-17 Proteins 0.000 claims description 55
- 102000019298 Lipocalin Human genes 0.000 claims description 46
- 108050006654 Lipocalin Proteins 0.000 claims description 46
- 108020001507 fusion proteins Proteins 0.000 claims description 41
- 102000037865 fusion proteins Human genes 0.000 claims description 41
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 claims description 40
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 claims description 39
- 108010065637 Interleukin-23 Proteins 0.000 claims description 13
- 102000013264 Interleukin-23 Human genes 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical class N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 239000002184 metal Chemical class 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 102000047202 human LCN2 Human genes 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000011616 biotin Chemical class 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical class C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 150000002739 metals Chemical class 0.000 claims description 3
- 108020001580 protein domains Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 239000003053 toxin Chemical class 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Chemical class 0.000 claims description 3
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 102000053162 human IL17A Human genes 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims 2
- 239000000824 cytostatic agent Chemical class 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 108010088751 Albumins Proteins 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 229920001515 polyalkylene glycol Polymers 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 2
- 101710186083 Interleukin-17 receptor A Proteins 0.000 description 2
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 2
- 108010057281 Lipocalin 1 Proteins 0.000 description 2
- 102100034724 Lipocalin-1 Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 108091006086 inhibitor proteins Proteins 0.000 description 2
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14169488.5 | 2014-05-22 | ||
| EP14169488 | 2014-05-22 | ||
| PCT/EP2015/061034 WO2015177175A2 (en) | 2014-05-22 | 2015-05-20 | Novel specific-binding polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020139064A Division JP7084965B2 (ja) | 2014-05-22 | 2020-08-20 | 特異的結合ポリペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017518748A JP2017518748A (ja) | 2017-07-13 |
| JP2017518748A5 true JP2017518748A5 (OSRAM) | 2018-06-28 |
| JP6753784B2 JP6753784B2 (ja) | 2020-09-09 |
Family
ID=50771150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568907A Expired - Fee Related JP6753784B2 (ja) | 2014-05-22 | 2015-05-20 | 特異的結合ポリペプチドおよびその使用 |
| JP2020139064A Active JP7084965B2 (ja) | 2014-05-22 | 2020-08-20 | 特異的結合ポリペプチドおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020139064A Active JP7084965B2 (ja) | 2014-05-22 | 2020-08-20 | 特異的結合ポリペプチドおよびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10774119B2 (OSRAM) |
| EP (2) | EP3789397B1 (OSRAM) |
| JP (2) | JP6753784B2 (OSRAM) |
| KR (1) | KR20170004011A (OSRAM) |
| CN (2) | CN113621050A (OSRAM) |
| AU (2) | AU2015261968B2 (OSRAM) |
| BR (1) | BR112016027024A2 (OSRAM) |
| CA (2) | CA2949405C (OSRAM) |
| DK (1) | DK3145945T3 (OSRAM) |
| ES (1) | ES2823563T3 (OSRAM) |
| MX (2) | MX384363B (OSRAM) |
| RU (1) | RU2723034C2 (OSRAM) |
| SG (2) | SG10201912019WA (OSRAM) |
| WO (1) | WO2015177175A2 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2891557A1 (en) | 2013-03-26 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| CN113621050A (zh) | 2014-05-22 | 2021-11-09 | 皮里斯制药有限公司 | 新型特异性结合多肽及其用途 |
| SG11201803732PA (en) * | 2015-11-30 | 2018-06-28 | Pieris Australia Pty Ltd | Novel anti-angiogenic fusion polypeptides |
| PT3583120T (pt) | 2017-02-17 | 2022-12-15 | Denali Therapeutics Inc | Polipeptídeos de ligação ao recetor de transferrina manipulados |
| US11077199B2 (en) | 2017-08-09 | 2021-08-03 | Massachusetts Institute Of Technology | Albumin binding peptide conjugates and methods thereof |
| JP2020530465A (ja) * | 2017-08-10 | 2020-10-22 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| CA3092551A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
| AU2019275733B2 (en) * | 2018-05-31 | 2025-07-31 | The Chinese University Of Hong Kong | Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities |
| EP3599245A1 (en) | 2018-07-27 | 2020-01-29 | Dompé farmaceutici S.p.A. | Il-17a binding polypeptides and medical uses thereof |
| CN109206485B (zh) * | 2018-09-27 | 2022-04-08 | 山东聚胜生物科技有限公司 | 一种防治肺癌转移的寡肽 |
| CN109180789B (zh) * | 2018-09-27 | 2022-08-19 | 上海揽微赛尔生物科技有限公司 | 一种寡肽及制药应用 |
| CN109096374B (zh) * | 2018-09-27 | 2022-11-18 | 深圳乐土沃森精准医疗有限公司 | 一种抑制肺癌转移的合成寡肽 |
| CN109096373B (zh) * | 2018-09-27 | 2022-06-21 | 江苏亨瑞生物医药科技有限公司 | 合成寡肽及其用途 |
| CN113939307A (zh) * | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| AU2021269222A1 (en) * | 2020-05-05 | 2023-01-19 | Janssen Biotech, Inc. | Methods of treating Crohn's disease with anti-IL23 specific antibody |
| CN114805546B (zh) * | 2022-06-08 | 2024-05-28 | 宁波市健康口腔医学研究院 | 一种检测口腔癌的t细胞表位多肽及其应用 |
| WO2025226984A1 (en) * | 2024-04-24 | 2025-10-30 | Mopac Biologics, Inc. | Human il-17 binding polypeptides |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3779221D1 (de) | 1986-08-19 | 1992-06-25 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| WO1995031479A1 (en) | 1994-05-18 | 1995-11-23 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| PL192364B1 (pl) | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| EP2899277A1 (en) * | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| US20070212703A1 (en) | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| TW200815469A (en) * | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| AU2007280398B2 (en) | 2006-08-01 | 2012-05-10 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| CN101516907B (zh) * | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| MX2009009079A (es) | 2007-02-23 | 2009-08-31 | Schering Corp | Anticuerpos anti-il-23p19 de ingenieria. |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| CA2702590A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| CA2713557C (en) * | 2008-01-30 | 2016-06-07 | Pieris Ag | Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same |
| EP2313430B1 (en) | 2008-06-24 | 2018-05-02 | Technische Universität München | Muteins of hngal and related proteins with affinity for a given target |
| US20110268818A1 (en) * | 2008-09-18 | 2011-11-03 | Jonathan Barasch | Ngal-binding siderophores and use thereof to treat iron deficiency and iron overload |
| US9549968B2 (en) | 2009-12-07 | 2017-01-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target |
| SMT201900297T1 (it) | 2010-06-08 | 2019-07-11 | Astrazeneca Ab | Muteine di lipocalina lacrimale che si legano a il-4 r alfa |
| CN110437321A (zh) | 2010-07-09 | 2019-11-12 | 阿菲博迪公司 | 多肽 |
| CA2808392C (en) | 2010-08-16 | 2020-03-10 | Pieris Ag | Binding proteins for hepcidin |
| DK2640740T3 (en) | 2010-11-15 | 2017-06-26 | Pieris Pharmaceuticals Gmbh | MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) |
| GB201100282D0 (en) * | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| UA117218C2 (uk) * | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| SG10201604566QA (en) | 2011-12-13 | 2016-07-28 | Pieris Ag | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| CA2891557A1 (en) * | 2013-03-26 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| CN113621050A (zh) | 2014-05-22 | 2021-11-09 | 皮里斯制药有限公司 | 新型特异性结合多肽及其用途 |
| SG10201906859PA (en) | 2015-01-28 | 2019-08-27 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| AR103714A1 (es) | 2015-02-18 | 2017-05-31 | Sanofi Sa | Proteínas específicas para pioverdina y pioquelina |
| US11261221B2 (en) | 2015-05-04 | 2022-03-01 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| CN107787327B (zh) | 2015-05-18 | 2022-02-08 | 皮里斯制药有限公司 | 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白 |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2015
- 2015-05-20 CN CN202110703906.XA patent/CN113621050A/zh active Pending
- 2015-05-20 ES ES15727573T patent/ES2823563T3/es active Active
- 2015-05-20 MX MX2016015235A patent/MX384363B/es unknown
- 2015-05-20 JP JP2016568907A patent/JP6753784B2/ja not_active Expired - Fee Related
- 2015-05-20 AU AU2015261968A patent/AU2015261968B2/en not_active Ceased
- 2015-05-20 CA CA2949405A patent/CA2949405C/en active Active
- 2015-05-20 SG SG10201912019WA patent/SG10201912019WA/en unknown
- 2015-05-20 US US15/312,094 patent/US10774119B2/en not_active Expired - Fee Related
- 2015-05-20 KR KR1020167035964A patent/KR20170004011A/ko not_active Ceased
- 2015-05-20 BR BR112016027024A patent/BR112016027024A2/pt not_active Application Discontinuation
- 2015-05-20 RU RU2016149596A patent/RU2723034C2/ru active
- 2015-05-20 WO PCT/EP2015/061034 patent/WO2015177175A2/en not_active Ceased
- 2015-05-20 CN CN201580040321.7A patent/CN106573964B/zh not_active Expired - Fee Related
- 2015-05-20 CA CA3170782A patent/CA3170782A1/en active Pending
- 2015-05-20 SG SG11201609274SA patent/SG11201609274SA/en unknown
- 2015-05-20 EP EP20185401.5A patent/EP3789397B1/en active Active
- 2015-05-20 DK DK15727573.6T patent/DK3145945T3/da active
- 2015-05-20 EP EP15727573.6A patent/EP3145945B1/en active Active
-
2016
- 2016-11-18 MX MX2021008318A patent/MX2021008318A/es unknown
-
2019
- 2019-02-13 AU AU2019201007A patent/AU2019201007B2/en not_active Ceased
-
2020
- 2020-08-06 US US16/987,218 patent/US11345728B2/en active Active
- 2020-08-20 JP JP2020139064A patent/JP7084965B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518748A5 (OSRAM) | ||
| RU2016149596A (ru) | Новые полипептиды со специфическим связыванием и пути их применения | |
| JP2018532372A5 (OSRAM) | ||
| JP2014502149A5 (OSRAM) | ||
| JP6475630B2 (ja) | ストレプトアビジン突然変異タンパク質およびそれらを使用する方法 | |
| Alfthan et al. | Properties of a single-chain antibody containing different linker peptides | |
| Dübel et al. | Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv) | |
| JP5004640B2 (ja) | 生理活性化合物の消失半減期延長のための方法及び組成物 | |
| JP3474574B2 (ja) | 結合特異性を有する組換ジスルフィド安定化ポリペプチドフラグメント | |
| JP2017527272A5 (OSRAM) | ||
| JP2019506140A5 (OSRAM) | ||
| JP2018519802A5 (OSRAM) | ||
| US6312916B1 (en) | Recombinant inactive core streptavidin mutants | |
| US8426557B2 (en) | IGF-1R binding polypeptides and their use | |
| KR102151289B1 (ko) | Abd 결합 폴리펩티드 | |
| JP2018515084A5 (OSRAM) | ||
| JP2020505948A5 (OSRAM) | ||
| JP2018519803A5 (OSRAM) | ||
| RU2019122482A (ru) | Мутеины липокалина с аффинностью связывания в отношении lag-3 | |
| RU2017128105A (ru) | Новые белки, специфические в отношении ангиогенеза | |
| CN105968204A (zh) | 一种抗前列腺特异性膜抗原的单域重链抗体 | |
| CN105968201A (zh) | 针对前列腺特异性膜抗原的单域重链抗体 | |
| AU2007242584A2 (en) | Novel polypeptides and use thereof | |
| AU2019380620B2 (en) | Novel triple-helical polypeptides lacking binding affinity for the Fc domain of immunoglobulin and uses thereof | |
| WO2005033130A2 (en) | Mutated ig binding domains of protein l |